Is tesamorelin legal? US, EU, and UK status

Tesamorelin is a prescription medicine in one country and an unlicensed product in most others. The short answer: the United States is the only jurisdiction where a manufacturer holds a marketing authorisation for tesamorelin, sold as Egrifta and Egrifta SV by Theratechnologies for a single approved indication. In the EU and UK, no authorised tesamorelin product exists. This article covers what that means jurisdiction by jurisdiction, and what the legal routes for access actually look like.

United States: FDA-approved as Egrifta for one narrow indication

The FDA granted marketing authorisation to tesamorelin (NDA/BLA 022505) in 2010. The current label specifies a single indication: reduction of excess abdominal fat in HIV-infected adult patients with lipodystrophy^[2]. A more concentrated reformulation, Egrifta SV, was approved in 2015 and is the current US presentation. Both brands are manufactured by Theratechnologies and are prescription-only; they are not available over the counter and are not sold directly to consumers without a valid US prescription.

The pivotal phase-3 trial that supported approval enrolled 404 HIV-infected patients with excess abdominal fat and ran for 26 weeks. Tesamorelin 2 mg daily subcutaneously reduced visceral adipose tissue by approximately 10.9% versus 0.6% on placebo^[3]. That trial evidence, and the longer extension-study data, underpin the FDA label. The label explicitly states the drug is not intended for weight-loss management and that its long-term cardiovascular safety has not been established.

Off-label prescribing in the US is common. Clinicians can legally prescribe any authorised medicine for uses beyond the label, and tesamorelin appears in body-composition, anti-ageing, and longevity clinics outside the HIV-lipodystrophy context. That off-label use is not supported by pivotal trial data, and the prescribing physician takes responsibility for any off-label decision. Online vendors selling tesamorelin outside of a licensed pharmacy and a valid prescription are operating outside this framework entirely.

European Union and EEA: no marketing authorisation since 2012

Theratechnologies (under the name Ferrer Internacional, S.A. at the time) submitted a centralised marketing-authorisation application to the EMA for Egrifta. The application was withdrawn on 21 June 2012 after the CHMP indicated it could not conclude on a positive benefit-risk balance^[1]. The CHMP's concerns included difficulty distinguishing lipodystrophy-related visceral fat from obesity-related fat in clinical practice, insufficient evidence of clinical meaningfulness, and a safety concern about elevated IGF-1 levels and theoretical cancer risk. No sponsor has submitted a re-application since.

As of the date of this article, there is no authorised tesamorelin product in any EU or EEA member state. This means general sale, importation for commercial purposes, and online supply to consumers are not lawful under EU pharmaceutical law. The fact that vendors will ship to EU addresses does not change this legal position, and customs services in EU countries may detain shipments.

Lawful access in the EU runs only through named-patient or compassionate-use routes. Under Article 83 of Regulation (EC) No 726/2004, national competent authorities can allow access to an unauthorised medicine for an individual patient with a serious condition when no satisfactory authorised treatment exists. Each member state administers this differently. Importantly, named-patient supply requires a prescribing clinician to initiate the request and take responsibility for it; the patient cannot self-import through this channel. See the relevant country pages at /peptides/tesamorelin#regulation for the specific framework in each jurisdiction.

United Kingdom: unlicensed, importable only via prescriber route

The UK MHRA has not granted a marketing authorisation for tesamorelin. No Egrifta or Egrifta SV product appears on the UK product licence register. After the UK left the EU in 2020, the MHRA became the national regulator; since the EMA authorisation was never granted in the first place, there was nothing to transition into UK law.

The UK's route for accessing an unlicensed medicine is via the 'specials' or named-patient import framework, administered by the MHRA. A licensed prescriber requests an unlicensed import for a specific patient on a named-patient basis^[5]. The prescriber takes clinical and legal responsibility for that decision. General importation, purchase, and supply without a prescriber's named-patient request is not a lawful route for UK residents. Customs may seize shipments entering the UK without the relevant documentation.

Private clinics in the UK sometimes offer peptide protocols that include tesamorelin. If they do so, the legal route is the named-patient framework above. Anyone consulting a UK clinic about tesamorelin should ask explicitly which route the clinic uses and whether they hold the required import documentation before agreeing to a prescription.

The off-label picture: what the evidence actually covers

Most community and clinic discussion of tesamorelin sits outside the approved indication. The off-label uses most often cited are visceral-fat reduction in people without HIV, body-composition improvement, sleep quality, and anti-ageing. Eric Topol, writing in his Ground Truths newsletter, noted that tesamorelin 'is being prescribed for healthy individuals to reduce abdominal fat, improve muscle mass and cognitive health,' and grouped it with other growth-hormone-releasing peptides as carrying 'the potential risk of cancer'^[4] on the basis of sustained IGF-1 elevation.

The trial programme that underpins the FDA approval is in the HIV-lipodystrophy population, on the labelled dose and schedule, for the labelled endpoint. There is no published phase-2 or phase-3 trial of tesamorelin for body composition, sleep, or longevity in people without HIV. What exists is a small number of ancillary analyses from the original programme and observational data from clinic settings. The gap between what the trials show and what is discussed in off-label contexts is wide.

The research-chemical supply chain and what it means

The legal gap between the US and the rest of the world is part of why tesamorelin circulates as a grey-market product online. Research-chemical vendors sell tesamorelin vials with 'not for human use' labelling and no quality oversight. Independent testing of grey-market peptide vials by consumer labs has found purity failures, incorrect concentrations, and contamination with particulates. The branded Theratechnologies product is manufactured to pharmaceutical standards under FDA oversight; products from unlicensed online vendors are not subject to any equivalent check. For US residents with a valid prescription, the lawful supply chain is a licensed US pharmacy dispensing Egrifta or Egrifta SV directly. For everyone else, there is no lawful route that bypasses the named-patient or compassionate-use frameworks described above.

What we do not yet know

The long-term cardiovascular safety of tesamorelin is not established, as the FDA label states explicitly. Cancer-risk data in non-HIV populations remain limited; sustained IGF-1 elevation is a theoretical concern that has not been ruled out or confirmed in long-duration studies. No sponsor has made a new regulatory submission to the EMA or MHRA since 2012, and whether that will change depends on commercial decisions by Theratechnologies or another party that we cannot predict. If and when a re-application is made, we will update this article and the regulation pages accordingly.

What this is not

This article does not constitute legal advice. Regulatory frameworks change, and this summary reflects our understanding as of June 2026. Individual circumstances vary: whether a specific import, prescription, or use falls within the law of your jurisdiction depends on facts we cannot assess here. A qualified legal professional in your jurisdiction is the right person to advise on the specific legality of any intended action.

This article is also not medical advice. Decisions about whether tesamorelin is appropriate for any individual, at any dose, on or off label, belong with a prescribing clinician who knows that person's medical history. The FDA label lists active malignancy, disrupted pituitary function (including history of pituitary surgery or head irradiation), and pregnancy as contraindications.

Where this lands

The legal status of tesamorelin is the clearest case in our peptide library: one jurisdiction with a real marketing authorisation (the US, for one narrow indication), and no authorisation anywhere else. For readers outside the US asking whether tesamorelin is legal, the honest answer is: not as an authorised medicine, and access via any route other than a prescriber-initiated named-patient import is outside the law. The cross-country regulation table on the tesamorelin peptide page and the per-country regulation detail cover the jurisdictional picture in more depth.